Bone fractures and prior abiraterone use in men treated with radium-223 plus enzalutamide for castration-resistant prostate cancer with bone metastases: a real-world study
Prostate Cancer and Prostatic Diseases, Published online: 31 October 2026; doi:10.1038/s41391-026-01170-z Bone fractures and prior abiraterone use in men treated with radium-223 plus enzalutamide for castration-resistant prostate cancer with bone metastases: a real-world study
Rana R. McKay, Orsolya Lunacsek, Matthew J. Korn, Amit D. Raval. Bone fractures and prior abiraterone use in men treated with radium-223 plus enzalutamide for castration-resistant prostate cancer with bone metastases: a real-world study. // Prostate Cancer and Prostatic Diseases. – 2026. – DOI: 10.1038/s41391-026-01170-z. – URL: https://www.nature.com/articles/s41391-026-01170-z
Rana R. McKay, Orsolya Lunacsek, Matthew J. Korn, & Amit D. Raval (2026). Bone fractures and prior abiraterone use in men treated with radium-223 plus enzalutamide for castration-resistant prostate cancer with bone metastases: a real-world study. Prostate Cancer and Prostatic Diseases. https://doi.org/10.1038/s41391-026-01170-z
Rana R. McKay, et al. “Bone fractures and prior abiraterone use in men treated with radium-223 plus enzalutamide for castration-resistant prostate cancer with bone metastases: a real-world study.” Prostate Cancer and Prostatic Diseases, 2026. doi:10.1038/s41391-026-01170-z.
@article{McKay2026,
title = {Bone fractures and prior abiraterone use in men treated with radium-223 plus enzalutamide for castration-resistant prostate cancer with bone metastases: a real-world study},
author = {McKay, Rana R. and Lunacsek, Orsolya and Korn, Matthew J. and Raval, Amit D.},
journal = {Prostate Cancer and Prostatic Diseases},
year = {2026},
doi = {10.1038/s41391-026-01170-z},
url = {https://www.nature.com/articles/s41391-026-01170-z}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...